WO2002083127A1 - Protein modification-inhibitory compositions - Google Patents

Protein modification-inhibitory compositions Download PDF

Info

Publication number
WO2002083127A1
WO2002083127A1 PCT/JP2002/003345 JP0203345W WO02083127A1 WO 2002083127 A1 WO2002083127 A1 WO 2002083127A1 JP 0203345 W JP0203345 W JP 0203345W WO 02083127 A1 WO02083127 A1 WO 02083127A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein modification
inhibitory compositions
compounds
tetrazole group
inhibitory
Prior art date
Application number
PCT/JP2002/003345
Other languages
French (fr)
Japanese (ja)
Inventor
Toshio Miyata
Original Assignee
Tokai University Educational System
Kurokawa, Kiyoshi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokai University Educational System, Kurokawa, Kiyoshi filed Critical Tokai University Educational System
Priority to JP2002580931A priority Critical patent/JPWO2002083127A1/en
Publication of WO2002083127A1 publication Critical patent/WO2002083127A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Protein modification-inhibitory compositions which contain as the active ingredient compounds having a tetrazole group or pharmacologically acceptable salts thereof. Compounds having a tetrazole group such as angiotensin receptor blockers are useful in inhibiting protein modification with carbonyl compounds caused by hyperglycemia or oxidation stress. These protein modification inhibitors are free from side effects such as vitamin B6 deficiency.
PCT/JP2002/003345 2001-04-09 2002-04-03 Protein modification-inhibitory compositions WO2002083127A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002580931A JPWO2002083127A1 (en) 2001-04-09 2002-04-03 Composition for inhibiting the production of modified protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001147115 2001-04-09
JP2001-147115 2001-04-09

Publications (1)

Publication Number Publication Date
WO2002083127A1 true WO2002083127A1 (en) 2002-10-24

Family

ID=18992647

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/003345 WO2002083127A1 (en) 2001-04-09 2002-04-03 Protein modification-inhibitory compositions

Country Status (2)

Country Link
JP (1) JPWO2002083127A1 (en)
WO (1) WO2002083127A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018649A1 (en) * 2003-08-25 2005-03-03 Nagoya Industrial Science Research Institute Agent for inhibiting the formation of final saccharification product
WO2005030737A1 (en) * 2003-09-30 2005-04-07 Sankyo Company, Limited Phenylene derivative having tetrazole ring or thiazolidinedione ring
WO2005051930A1 (en) * 2003-11-27 2005-06-09 Tokai University Educational System Modified-protein formation inhibitor
WO2006028007A1 (en) * 2004-09-06 2006-03-16 Kowa Co., Ltd. Remedy for glomerular diseae
WO2007026962A1 (en) * 2005-08-31 2007-03-08 Daiichi Sankyo Company, Limited Phenylene derivative
JPWO2005054205A1 (en) * 2003-12-05 2007-06-28 学校法人東海大学 Protein modification product inhibitor
US7417052B2 (en) 2004-09-29 2008-08-26 Sankyo Company, Limited Phenylene derivative having tetrazole ring or thiazolidinedione ring

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252753A (en) * 1991-11-01 1993-10-12 Ortho Pharmaceutical Corporation Process for the preparation of certain substituted biphenyl tetrazoles and compounds thereof
WO1999063930A2 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel angiotensin receptor modulators and their uses
WO2000038676A1 (en) * 1998-12-23 2000-07-06 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252753A (en) * 1991-11-01 1993-10-12 Ortho Pharmaceutical Corporation Process for the preparation of certain substituted biphenyl tetrazoles and compounds thereof
WO1999063930A2 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel angiotensin receptor modulators and their uses
WO2000038676A1 (en) * 1998-12-23 2000-07-06 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018649A1 (en) * 2003-08-25 2005-03-03 Nagoya Industrial Science Research Institute Agent for inhibiting the formation of final saccharification product
WO2005030737A1 (en) * 2003-09-30 2005-04-07 Sankyo Company, Limited Phenylene derivative having tetrazole ring or thiazolidinedione ring
WO2005051930A1 (en) * 2003-11-27 2005-06-09 Tokai University Educational System Modified-protein formation inhibitor
JPWO2005054205A1 (en) * 2003-12-05 2007-06-28 学校法人東海大学 Protein modification product inhibitor
JP4837992B2 (en) * 2003-12-05 2011-12-14 学校法人東海大学 Protein modification product inhibitor
WO2006028007A1 (en) * 2004-09-06 2006-03-16 Kowa Co., Ltd. Remedy for glomerular diseae
JPWO2006028007A1 (en) * 2004-09-06 2008-05-08 興和株式会社 Treatment for glomerular diseases
US7417052B2 (en) 2004-09-29 2008-08-26 Sankyo Company, Limited Phenylene derivative having tetrazole ring or thiazolidinedione ring
WO2007026962A1 (en) * 2005-08-31 2007-03-08 Daiichi Sankyo Company, Limited Phenylene derivative

Also Published As

Publication number Publication date
JPWO2002083127A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
EG25251A (en) Synergistic fungicidal compositions.
WO2008081399A3 (en) 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
EP1650192A4 (en) Quinolone derivative or salt thereof
HK1067863A1 (en) Compositions for potentiating glutathione
AP2405A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms.
ZA200305993B (en) Herbicidal compositions.
WO2008006528A3 (en) Pharmaceutical compositions comprising levetiracetam
WO2005077932A3 (en) Chemokine receptor antagonists
HK1062557A1 (en) Compositions for delivering bisphosphonates
WO2007067506A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
EP1900362A3 (en) Alfa-aminoamide derivatives useful in the treatment of addictive disorders
AU2003255845A1 (en) Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
ZA200408670B (en) Trizole derivatives as tachykinin receptor antagonists.
PL1833299T3 (en) Fungicidal active ingredient combinations containing fluoxastrobin
WO2009016560A3 (en) Trans-3-aza-bicyclo[3.1.0]hexane derivatives
IL180397A0 (en) Diamine derivatives, fungicidal compositions containing the same, and processes for the preparation thereof
WO2006102112A3 (en) Prokineticin 1 receptor
AP2005003195A0 (en) Herbicidal compositions.
IL181634A (en) Topical pharmaceutical compositions comprising 8-pyrazolylmethyl-1,3,7-trihydropurine-2,6-dione derivatives useful for wound healing
WO2007003264A3 (en) Polyaspartic acid derivatives in covering agents containing polysiloxane
AU2002309038A1 (en) Compositions for transmucosal administration containing coenzyme Q as the active ingredient
MXPA03006991A (en) Piperidinee derivatives as neurokinin 1 antagonists.
WO2007087026A3 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof
WO2002083127A1 (en) Protein modification-inhibitory compositions
TW200733963A (en) Cough inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002580931

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase